STOCK TITAN

[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Spruce Biosciences (SPRB) reported an insider equity event by its Chief Executive Officer and director. On 10/20/2025, the Board certified performance goals, causing 4,784 performance‑based RSUs granted on March 14, 2024 to vest. Each RSU represents the right to receive one share of SPRB common stock.

In connection with the vesting, 1,539 shares were withheld for taxes at a price of $148.16, resulting in a net issuance of 3,245 shares. Following these transactions, the reporting person directly beneficially owned 9,474 shares. The Form 4 reflects an “M” code for settlement of RSUs into common stock at $0 and an “F” code for tax withholding.

Spruce Biosciences (SPRB) ha riportato un evento interno di capitale da parte del suo Chief Executive Officer e direttore. Il 20/10/2025, il Consiglio ha certificato gli obiettivi di performance, causando la vesting di 4.784 RSU basate sulle performance concesse il 14 marzo 2024. Ogni RSU conferisce il diritto a ricevere una quota delle azioni ordinarie SPRB.

In relazione all'atto di vesting, sono state trattenute 1.539 azioni a fini fiscali al prezzo di $148,16, con conseguente emissione netta di 3.245 azioni. Dopo tali operazioni, la persona riportata possedeva direttamente 9.474 azioni delle azioni ordinarie SPRB. Il Modulo 4 riflette un codice “M” per l'adeguamento degli RSU in azioni ordinarie a $0 e un codice “F” per la ritenuta fiscale.

Spruce Biosciences (SPRB) informó un evento de incremento de capital por parte de su Director Ejecutivo y director. El 20/10/2025, la Junta certificó los objetivos de rendimiento, haciendo que se venzan 4.784 RSU basadas en rendimiento otorgadas el 14 de marzo de 2024. Cada RSU representa el derecho a recibir una acción ordinaria SPRB.

En relación con la adquisición, 1.539 acciones fueron retenidas para impuestos a un precio de $148.16, resultando en una emisión neta de 3.245 acciones. Tras estas operaciones, la persona reportante poseía directamente 9.474 acciones de SPRB. El Formulario 4 refleja un código “M” para el liquidación de RSU en acciones ordinarias a $0 y un código “F” para la retención de impuestos.

Spruce Biosciences (SPRB) 최고경영자 겸 이사가 내부 자본 이벤트를 보고했습니다. 2025년 10월 20일, 이사회가 성과 목표를 인증했고, 2024년 3월 14일에 부여된 성과 기반 RSU 4,784개가 취득되었습니다. 각 RSU는 SPRB 보통주 1주를 받을 수 있는 권리를 나타냅니다.

취득과 관련하여, 1,539주가 세금 원천징수를 위해 보유되었고 가격은 $148.16로, 결과적으로 실질 발행 주식 3,245주가 되었습니다. 이 거래 이후 보고자가 직접적으로 실질적으로 9,474주의 보유 주식을 소유하게 되었습니다. Form 4는 RSU를 보통주로의 정산에 대한 “M” 코드와 세금 원천징수에 대한 “F” 코드를 반영합니다.

Spruce Biosciences (SPRB) a déclaré un événement d'initié par son PDG et administrateur. Le 20/10/2025, le Conseil a certifié les objectifs de performance, entraînant la vesting de 4 784 RSU basées sur la performance accordées le 14 mars 2024. Chaque RSU donne le droit de recevoir une action ordinaire SPRB.

Dans le cadre du vesting, 1 539 actions ont été retenues pour les impôts au prix de $148,16, ce qui donne une émission nette de 3 245 actions. Suite à ces transactions, la personne déclarant détenait directement 9 474 actions.

Le Formulaire 4 reflète un code “M” pour le règlement des RSU en actions ordinaires à $0 et un code “F” pour la retenue d'impôt.

Spruce Biosciences (SPRB) meldete eine Insider-Eigenkapitaltransaktion durch seinen CEO und Direktor. Am 20.10.2025 bestätigte der Vorstand die Leistungsziele, wodurch 4.784 leistungsbasierte RSU vergeben am 14. März 2024 vesten. Jede RSU berechtigt zum Erhalt von einer SPRB-Stammeinheit.

Im Zusammenhang mit dem Vesting wurden 1.539 Aktien zur Steuer einbehalten zum Preis von $148,16, was zu einer Nettogewinnung von 3.245 Aktien führte. Nach diesen Transaktionen hielt die meldende Person unmittelbar und vorteilhaft 9.474 Aktien. Das Formular 4 zeigt einen „M“-Code für die Abwicklung der RSUs in Stammaktien zu $0 und einen „F“-Code für die Steuerabzug.

Spruce Biosciences (SPRB) أبلغت عن حدث داخلي للمساهمة من قبل الرئيس التنفيذي والمدير. في 20/10/2025، صوت المجلس على أهداف الأداء، مما أدى إلى vesting لـ 4,784 RSU قائمة على الأداء ممنوحة في 14 مارس 2024. يمثل كل RSU حقاً في تلقي سهم واحد من أسهم SPRB العادية.

فيما يتعلق بال vesting، تم حجز 1,539 سهم للضرائب بسعر $148.16، مما أدى إلى إصدار صافي قدره 3,245 سهم. عقب هذه المعاملات، امتلك الشخص المُبلّغ بشكل مباشر ومستفيد 9,474 سهم. يعكس النموذج 4 رمز “M” لتسوية RSU إلى أسهم عادية ورمز “F” لاقتطاع الضرائب.

Spruce Biosciences (SPRB) 通过其首席执行官兼董事报告了内部股权事件。于 2025/10/20,董事会认证了业绩目标,导致在 2024/3/14 授予的 4,784 份基于业绩的 RSU 归属。每份 RSU 代表获得一股 SPRB 普通股的权利。

在归属相关的交易中,为税务而预扣了 1,539 股,价格为 $148.16,从而产生净发行量为 3,245 股。在这些交易之后,披露人直接受益地拥有 9,474 股。Form 4 显示用于将 RSU 结算为普通股的“M”代码,以及用于扣税的“F”代码。

Positive
  • None.
Negative
  • None.

Insights

Routine RSU vesting with tax withholding; neutral for valuation.

The CEO’s performance-based RSUs vested after the Board certified goals on 10/20/2025, converting 4,784 RSUs into common shares. Form 4 codes show an “M” (RSU settlement at $0) and an “F” (shares withheld for taxes).

Tax coverage used 1,539 shares at $148.16, yielding a net issuance of 3,245 shares. Post-transaction direct beneficial ownership is 9,474 shares. These are standard administrative entries tied to equity compensation rather than new market purchases or sales.

The filing indicates no remaining RSUs from this grant after settlement. Actual trading impact is typically minimal for such withholding events.

Spruce Biosciences (SPRB) ha riportato un evento interno di capitale da parte del suo Chief Executive Officer e direttore. Il 20/10/2025, il Consiglio ha certificato gli obiettivi di performance, causando la vesting di 4.784 RSU basate sulle performance concesse il 14 marzo 2024. Ogni RSU conferisce il diritto a ricevere una quota delle azioni ordinarie SPRB.

In relazione all'atto di vesting, sono state trattenute 1.539 azioni a fini fiscali al prezzo di $148,16, con conseguente emissione netta di 3.245 azioni. Dopo tali operazioni, la persona riportata possedeva direttamente 9.474 azioni delle azioni ordinarie SPRB. Il Modulo 4 riflette un codice “M” per l'adeguamento degli RSU in azioni ordinarie a $0 e un codice “F” per la ritenuta fiscale.

Spruce Biosciences (SPRB) informó un evento de incremento de capital por parte de su Director Ejecutivo y director. El 20/10/2025, la Junta certificó los objetivos de rendimiento, haciendo que se venzan 4.784 RSU basadas en rendimiento otorgadas el 14 de marzo de 2024. Cada RSU representa el derecho a recibir una acción ordinaria SPRB.

En relación con la adquisición, 1.539 acciones fueron retenidas para impuestos a un precio de $148.16, resultando en una emisión neta de 3.245 acciones. Tras estas operaciones, la persona reportante poseía directamente 9.474 acciones de SPRB. El Formulario 4 refleja un código “M” para el liquidación de RSU en acciones ordinarias a $0 y un código “F” para la retención de impuestos.

Spruce Biosciences (SPRB) 최고경영자 겸 이사가 내부 자본 이벤트를 보고했습니다. 2025년 10월 20일, 이사회가 성과 목표를 인증했고, 2024년 3월 14일에 부여된 성과 기반 RSU 4,784개가 취득되었습니다. 각 RSU는 SPRB 보통주 1주를 받을 수 있는 권리를 나타냅니다.

취득과 관련하여, 1,539주가 세금 원천징수를 위해 보유되었고 가격은 $148.16로, 결과적으로 실질 발행 주식 3,245주가 되었습니다. 이 거래 이후 보고자가 직접적으로 실질적으로 9,474주의 보유 주식을 소유하게 되었습니다. Form 4는 RSU를 보통주로의 정산에 대한 “M” 코드와 세금 원천징수에 대한 “F” 코드를 반영합니다.

Spruce Biosciences (SPRB) a déclaré un événement d'initié par son PDG et administrateur. Le 20/10/2025, le Conseil a certifié les objectifs de performance, entraînant la vesting de 4 784 RSU basées sur la performance accordées le 14 mars 2024. Chaque RSU donne le droit de recevoir une action ordinaire SPRB.

Dans le cadre du vesting, 1 539 actions ont été retenues pour les impôts au prix de $148,16, ce qui donne une émission nette de 3 245 actions. Suite à ces transactions, la personne déclarant détenait directement 9 474 actions.

Le Formulaire 4 reflète un code “M” pour le règlement des RSU en actions ordinaires à $0 et un code “F” pour la retenue d'impôt.

Spruce Biosciences (SPRB) meldete eine Insider-Eigenkapitaltransaktion durch seinen CEO und Direktor. Am 20.10.2025 bestätigte der Vorstand die Leistungsziele, wodurch 4.784 leistungsbasierte RSU vergeben am 14. März 2024 vesten. Jede RSU berechtigt zum Erhalt von einer SPRB-Stammeinheit.

Im Zusammenhang mit dem Vesting wurden 1.539 Aktien zur Steuer einbehalten zum Preis von $148,16, was zu einer Nettogewinnung von 3.245 Aktien führte. Nach diesen Transaktionen hielt die meldende Person unmittelbar und vorteilhaft 9.474 Aktien. Das Formular 4 zeigt einen „M“-Code für die Abwicklung der RSUs in Stammaktien zu $0 und einen „F“-Code für die Steuerabzug.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Szwarcberg Javier B.

(Last) (First) (Middle)
C/O SPRUCE BIOSCIENCES, INC.
611 GATEWAY BOULEVARD, SUITE 740

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/20/2025 M 4,784(1) A $0(2) 11,013 D
Common Stock 10/20/2025 F 1,539(1) D $148.16 9,474 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0(2) 10/20/2025 A 4,784 (1) (1) Common Stock 4,784 $0 4,784 D
Restricted Stock Units $0(2) 10/20/2025 M 4,784 (1) (1) Common Stock 4,784 $0 0 D
Explanation of Responses:
1. On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock.
/s/ Samir Gharib, Attorney-in-Fact 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SPRB report on 10/20/2025?

The CEO and director reported vesting of 4,784 performance-based RSUs and tax withholding of 1,539 shares.

How many SPRB shares were issued net after tax withholding?

Net issuance was 3,245 shares after withholding 1,539 shares for taxes.

What price was used for SPRB share tax withholding?

Shares were withheld for taxes at $148.16 per share.

How many SPRB shares does the reporting person own after the transactions?

Direct beneficial ownership is 9,474 shares following the reported transactions.

What do the Form 4 transaction codes M and F mean for SPRB?

“M” indicates RSU settlement into common stock at $0; “F” indicates shares withheld for taxes.

When were the RSUs that vested on 10/20/2025 originally granted?

They were granted on March 14, 2024 as performance-based RSUs.
Spruce Biosciences, Inc.

NASDAQ:SPRB

SPRB Rankings

SPRB Latest News

SPRB Latest SEC Filings

SPRB Stock Data

72.99M
550.44k
2.32%
21.05%
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO